CN116262934B - 转录单元及制备空壳腺相关病毒的方法 - Google Patents
转录单元及制备空壳腺相关病毒的方法 Download PDFInfo
- Publication number
- CN116262934B CN116262934B CN202210628425.1A CN202210628425A CN116262934B CN 116262934 B CN116262934 B CN 116262934B CN 202210628425 A CN202210628425 A CN 202210628425A CN 116262934 B CN116262934 B CN 116262934B
- Authority
- CN
- China
- Prior art keywords
- aav
- promoter
- virus
- cap
- empty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 43
- 238000013518 transcription Methods 0.000 title claims abstract description 34
- 230000035897 transcription Effects 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title abstract description 29
- 101150044789 Cap gene Proteins 0.000 claims abstract description 43
- 239000013604 expression vector Substances 0.000 claims description 43
- 239000013612 plasmid Substances 0.000 claims description 23
- 238000004806 packaging method and process Methods 0.000 claims description 17
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 12
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 108020004688 Small Nuclear RNA Proteins 0.000 claims description 7
- 102000039471 Small Nuclear RNA Human genes 0.000 claims description 7
- 241000713880 Spleen focus-forming virus Species 0.000 claims description 7
- 101150066583 rep gene Proteins 0.000 claims description 7
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 6
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 claims description 6
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 claims description 6
- 108091036078 conserved sequence Proteins 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000002103 transcriptional effect Effects 0.000 claims description 5
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 52
- 210000004907 gland Anatomy 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 24
- 210000000234 capsid Anatomy 0.000 description 23
- 108090000565 Capsid Proteins Proteins 0.000 description 17
- 102100023321 Ceruloplasmin Human genes 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 239000013598 vector Substances 0.000 description 11
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 6
- 241000701447 unidentified baculovirus Species 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 5
- 229960004359 iodixanol Drugs 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 238000000432 density-gradient centrifugation Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012096 transfection reagent Substances 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091026838 U1 spliceosomal RNA Proteins 0.000 description 1
- 108700013125 Zolgensma Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229950009805 onasemnogene abeparvovec Drugs 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
生产方法 | 辅助载体 | Rep-Cap表达载体 | Cap表达载体 | 包装细胞 | 细胞量 |
直接分离法 | phelper | P5-rep-P40-cap2 | / | 293T | 3.6×109 |
杆状病毒法 | / | PH-rep-P10-cap2 | / | Sf9 | 3.6×109 |
本发明方法 | phelper | / | CMV-AAV2 cap | 293T | 1.8×109 |
生产方法 | 空壳腺相关病毒总产量 | 单细胞产量 |
直接分离法 | 31.429μg | 8.73fg |
杆状病毒法 | 92.38μg | 25.66fg |
本发明方法 | 184.41μg | 102.44fg |
AAV血清型 | Cap表达载体 | 293T包装细胞量 | 空壳腺相关病毒总产量 |
AAV2 | CMV-Cap2 | 3.6×109 | 150.25μg |
AAV2 | CMV-AAV2 cap-mt | 3.6×109 | 565.98μg |
AAV8 | CMV-AAV8 cap-mt | 3.6×109 | 2653.29μg |
AAV9 | CMV-AAV9 cap-mt | 3.6×109 | 1206.21μg |
Claims (8)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021115337357 | 2021-12-15 | ||
CN202111533735 | 2021-12-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116262934A CN116262934A (zh) | 2023-06-16 |
CN116262934B true CN116262934B (zh) | 2024-03-01 |
Family
ID=86723743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210628425.1A Active CN116262934B (zh) | 2021-12-15 | 2022-06-06 | 转录单元及制备空壳腺相关病毒的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116262934B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6329181B1 (en) * | 2000-08-07 | 2001-12-11 | Neurologix, Inc. | Helper functions for recombinant vector production |
CN112912506A (zh) * | 2018-10-17 | 2021-06-04 | 葛兰素史克知识产权开发有限公司 | 腺相关病毒载体生产细胞系 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012064960A2 (en) * | 2010-11-10 | 2012-05-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination |
WO2017108931A1 (en) * | 2015-12-22 | 2017-06-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Improved hybrid dual recombinant aav vector systems for gene therapy |
-
2022
- 2022-06-06 CN CN202210628425.1A patent/CN116262934B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6329181B1 (en) * | 2000-08-07 | 2001-12-11 | Neurologix, Inc. | Helper functions for recombinant vector production |
CN112912506A (zh) * | 2018-10-17 | 2021-06-04 | 葛兰素史克知识产权开发有限公司 | 腺相关病毒载体生产细胞系 |
Non-Patent Citations (4)
Title |
---|
Green,M.R..GenBank: V01457.1.Genbank.1989,参见核苷酸序列信息. * |
High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids;L Cao 等;J Virol.;第74卷(第24期);参见摘要 * |
Intron splicing-mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells;Haifeng Chen等;Mol Ther.;第16卷(第5期);参见摘要 * |
Manufacturing of adeno-associated viruses, for example: AAV2;Haifeng Chen;Methods Mol Biol.;第737卷;参见摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN116262934A (zh) | 2023-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Robert et al. | Manufacturing of recombinant adeno‐associated viruses using mammalian expression platforms | |
JP6165752B2 (ja) | アデノ随伴ウイルスの産生のための細胞株 | |
Ayuso et al. | Production, purification and characterization of adeno-associated vectors | |
JP4559429B2 (ja) | 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法 | |
US11180736B2 (en) | Method of preparing recombinant adeno-associated virus and recombinant baculovirus | |
Qu et al. | Scalable downstream strategies for purification of recombinant adeno-associated virus vectors in light of the properties | |
KR102612563B1 (ko) | 변형된 포스포리파제 도메인을 갖는 아데노-연관 바이러스 (aav) | |
US20230159953A1 (en) | Closed-ended, linear, duplex adenoassociated virus dna, and uses thereof | |
JP2023171525A (ja) | Aavキメラ | |
CN114150021B (zh) | 一种包含重叠开放阅读框的基因的表达盒及其在昆虫细胞中的应用 | |
EP4150101A2 (en) | Methods and compositions for purifying adeno associated virus particles or adenoviruses | |
CN116262934B (zh) | 转录单元及制备空壳腺相关病毒的方法 | |
WO2023060113A1 (en) | Compositions and methods for recombinant aav production | |
AU2022360254A1 (en) | Compositions and methods for recombinant aav production | |
WO2024079655A1 (en) | Chromatography methods for purification of aav capsids | |
KR20240082394A (ko) | 재조합 aav 제조를 위한 조성물 및 방법 | |
WO2021041375A1 (en) | Compositions and methods for producing adeno-associated viral vectors | |
Cho et al. | Improved Production Efficiencies of Various Adeno-Associated Virus (AAV) Serotypes and a Novel Universal AAV Titration Method | |
AU2016202153A1 (en) | Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV in insect cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Country or region after: China Address after: Room d301-d309, Guangzhou International Business Incubator (Zone D), No.3, Juquan Road, Science City, Guangzhou hi tech Industrial Development Zone, Guangzhou 510000, Guangdong Province Applicant after: Yunzhou Biotechnology (Guangzhou) Co.,Ltd. Address before: Room d301-d309, Guangzhou International Business Incubator (Zone D), No. 3, Juquan Road, Science City, high tech Industrial Development Zone, Guangzhou, Guangdong 510000 Applicant before: YUNZHOU BIOSCIENCES (GUANGZHOU) Inc. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |